Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 31, 2014

View Archived Issues

Clovis Oncology plans big year for 2014

Multiple pivotal phase III trials under way at Array BioPharma

Avanir Pharmaceuticals submits NDA for AVP-825 for migraine

Advanced Proteome Therapeutics provides update on modified proteins for cancer

Enrollment opened in phase II study of GLPG-0634 in Crohn's disease

FDA accepts NDA filing for budesonide foam for distal ulcerative colitis

Phase II trial of tivozanib in breast cancer discontinued

PCI Biotech awarded grant from the Research Council of Norway

Researchers at Bristol-Myers Squibb prepare new XIAP inhibitors for cancer

Amgen offers overview of fourth quarter 2013

Merck & Co. discloses novel agents for HIV infection

Novel antibodies claimed by OncoMed Pharmaceuticals for cancer

Japanese group discloses new antitumor agent

NeoGenomics launches 22 NeoTYPE genomic profiling tests for cancer

Amarantus and Boston University to evaluate test for early signs of neurodegenerative diseases

Drug developed for diabetes ameliorates experimental SMA

DSP and Edison Pharmaceuticals expand cooperation for mitochondrial disease

Asahi Kasei and Zosano discontinue development of Teribone transdermal patch

Eureka Therapeutics and Memorial Sloan-Kettering Cancer Center licenses anticancer MAb to Novartis

Amgen's RUTHERFORD-2 phase III trial of evolocumab in HeFH meets primary endpoints

AstraZeneca to join VIB and CD3 in development of MALT1 inhibitors

Unique HSP 90 inhibitor does not induce prosurvival heat shock response

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.